Athanasios Georgas

Papers

1

Total Citations

12

H-Index

1

About

Dr. Athanasios Georgas is a pioneering ophthalmologist whose research centers on the intersection of radiation oncology and retinal disease, particularly neovascular age-related macular degeneration (nAMD). His landmark contribution is the STAR trial, a pivotal, double-masked, sham-controlled study evaluating stereotactic radiotherapy as a novel treatment for nAMD. This work demonstrated that precisely targeted ionizing radiation can mitigate key pathogenic processes underlying the disease, potentially reducing the burden of frequent anti-VEGF injections. With 12 citations since its 2024 publication, the STAR trial has already shaped clinical discourse, offering a paradigm-shifting approach to a leading cause of blindness. Dr. Georgas’s research addresses the critical unmet need for durable, non-invasive therapies, positioning him at the forefront of translational retinal therapeutics. His rigorous methodology—combining device innovation with gold-standard trial design—exemplifies how interdisciplinary science can transform patient care. For students and researchers, his work underscores the power of challenging treatment conventions through evidence-based innovation.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
12 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 46

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago